An antibody, pharmaceutical conjugate thereof and use thereof
CN122302064APending Publication Date: 2026-06-30EVOPOINT BIOSCIENCES CO LTD
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- EVOPOINT BIOSCIENCES CO LTD
- Filing Date
- 2022-09-27
- Publication Date
- 2026-06-30
AI Technical Summary
Technical Problem
The lack of effective monoclonal antibody or ADC drugs targeting Claudin18.2 in current technology, especially in patients with HER2-negative gastric cancer, results in a lack of treatment options and a poor survival rate.
Method used
An anti-Claudin18.2 antibody-drug conjugate (ADC) has been developed, which contains specific heavy chain variable regions and light chain variable regions (CDRs) that can efficiently recognize and bind to Claudin18.2. By linking cytotoxic drugs through a linker, targeted therapy on Claudin18.2-positive tumors can be achieved.
Benefits of technology
It significantly prolongs progression-free survival and overall survival in patients with locally advanced or metastatic gastric cancer, providing a wider range of superior treatment options.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
This invention relates to antibodies and antibody-drug conjugates, and more particularly to antibodies targeting Claudin18.2 (CLDN18.2) and antibody-drug conjugates (ADCs), as well as compositions containing said antibodies and ADC molecules and their therapeutic applications.
Need to check novelty before this filing date? Find Prior Art